Text Size

Ehealth: Second Life Impacts Diabetes Education & Self-Management (SLIDES)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Duke University
ClinicalTrials.gov Identifier:
NCT01186965
First received: August 19, 2010
Last updated: September 10, 2012
Last verified: September 2012
History of Changes
  Purpose

The purpose of this study is to to develop and evaluate the feasibility, usability, and effect of participation in SLIDES (a virtual diabetes community in Second Life) for providing interactive diabetes education, support, and resources.


Condition Intervention
Type 2 Diabetes
 Behavioral: eHealth program in the VE platform Second Life

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Supportive Care
Official Title: Ehealth: Second Life Impacts Diabetes Education & Self-Management

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Duke University:

Primary Outcome Measures:
  • Perceived Usefulness [ Time Frame: 3 and 6 months ] [ Designated as safety issue: No ]
  • Perceived Ease of Use [ Time Frame: 3 and 6 months ] [ Designated as safety issue: No ]
  • Process data [ Time Frame: January 2011 through May 2012 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Demographics [ Time Frame: baseline ] [ Designated as safety issue: No ]
  • Metabolic Indicators [ Time Frame: baseline, 3 months, 6 months ] [ Designated as safety issue: No ]
  • Diabetes knowledge [ Time Frame: baseline, 3 months, 6 months ] [ Designated as safety issue: No ]

Enrollment: 20
Study Start Date: January 2011
Estimated Study Completion Date: January 2013
Primary Completion Date: August 2012 (Final data collection date for primary outcome measure)
Intervention Details:
    Behavioral: eHealth program in the VE platform Second Life
    determine the feasibility and acceptability of an eHealth program that provides diabetes education and self-management support.
    Other Name: Second Life
  Eligibility

Ages Eligible for Study:   21 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • current Duke Endocrinology patient
  • are between 21 and 75 years old
  • are able to speak and read English
  • are computer literate (have used a computer for at least 6 months)
  • understand how to use the Internet (have accessed the Internet on at least 6 occasions)
  • have access to a computer with a non-dial-up Internet connection in a private location (home)
  • are mentally capable of informed consent
  • are reachable by telephone
  • have no pre-existing medical condition(s) or severe diabetes related complications that would interfere with study participation (i.e., physical activity) or measures (e.g., renal failure, Stage III hypertension, severe orthopedic conditions or joint replacement scheduled within 6 months, paralysis, bleeding disorders, cancer, or receipt of pharmacologic doses of anti-coagulant medications [warfarin])
  • are able to travel to DUMC for follow-up appointments.

Exclusion Criteria:

-

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01186965

Locations
United States, North Carolina
Duke University Medical Center
Durham, North Carolina, United States, 27710
Sponsors and Collaborators
Duke University
Investigators
Principal Investigator: Constance M Johnson, PhD Duke University School of Nursing
  More Information

No publications provided

Responsible Party: Duke University
ClinicalTrials.gov Identifier: NCT01186965     History of Changes
Other Study ID Numbers: Pro00022132, R21-LM010727-02
Study First Received: August 19, 2010
Last Updated: September 10, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by Duke University:
Diabetes
Second Life
virtual community
diabetes education
diabetes support group

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases

ClinicalTrials.gov processed this record on May 23, 2013